# 1 Contrasting genomic epidemiology between sympatric *Plasmodium*

# 2 falciparum and Plasmodium vivax populations

- 3
- 4 Philipp Schwabl<sup>1,2\*</sup>, Flavia Camponovo<sup>3,4,5\*</sup>, Collette Clementson<sup>6</sup>, Angela M. Early<sup>2</sup>, Margaret
- 5 Laws<sup>1,2</sup>, David A. Forero-Peña<sup>7</sup>, Oscar Noya<sup>8,9</sup>, María Eugenia Grillet<sup>10</sup>, Mathieu Vanhove<sup>1,2</sup>,
- 6 Frank Anthony<sup>6</sup>, Kashana James<sup>6</sup>, Narine Singh<sup>6</sup>, Horace Cox<sup>6,11</sup>, Reza Niles-Robin<sup>6</sup>, Caroline
- 7 O. Buckee<sup>3</sup>, Daniel E. Neafsey<sup>1,2</sup>
- 8
- <sup>1</sup> Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
- 10 Health, Boston, MA, USA
- <sup>2</sup> Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge,
- 12 MA, USA
- <sup>3</sup> Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H.
- 14 Chan School of Public Health, Boston, MA, USA
- <sup>4</sup> Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute,
- 16 Basel, Switzerland
- 17 <sup>5</sup> University of Basel, Basel, Switzerland
- 18 <sup>6</sup> National Malaria Program, Ministry of Health, Georgetown, Guyana
- 19<sup>7</sup> Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolívar, Venezuela
- <sup>8</sup> Institute of Tropical Medicine, Faculty of Medicine, Central University of Venezuela, Caracas,
- 21 Venezuela
- <sup>9</sup> Center for Malaria Research, Institute of Higher Studies 'Dr. Arnoldo Gabaldon', Ministry of
- 23 People's Power for Health, Caracas, Venezuela
- <sup>10</sup> Institute of Zoology and Tropical Ecology, Central University of Venezuela, Caracas,
- 25 Venezuela
- 26 <sup>11</sup> Caribbean Public Health Agency, Port of Spain, Trinidad and Tobago
- 27
- 28 <sup>\*</sup>equal contributions
- 29
- 30
- 31 <u>Keywords</u>: *Plasmodium falciparum*; *Plasmodium vivax*; malaria; genomic epidemiology, Guyana
- 32

# 33 Abstract

34 The malaria parasites Plasmodium falciparum and Plasmodium vivax differ in key biological 35 processes and associated clinical effects, but consequences on population-level transmission 36 dynamics are difficult to predict. This co-endemic malaria study from Guyana details important 37 epidemiological contrasts between the species by coupling population genomics (1,396 38 spatiotemporally-matched parasite genomes) with sociodemographic analysis (nationwide 39 patient census). We describe how P. falciparum forms large, interrelated subpopulations that 40 sporadically expand but generally exhibit restrained dispersal, whereby spatial distance and 41 patient travel statistics predict parasite identity-by-descent (IBD). Case bias towards working-42 age adults is also strongly pronounced. P. vivax exhibits 46% higher average diversity ( $\pi$ ) and 43 6.5x lower average IBD. It occupies a wider geographic range, without evidence for outbreak-44 like expansions, only microgeographic patterns of isolation-by-distance, and weaker case bias 45 towards adults. Possible latency-relapse effects also manifest in various analyses. For example, 46 11.0% of patients diagnosed with P. vivax in Greater Georgetown report no recent travel to 47 endemic zones, and *P. vivax* clones recur in 11/46 patients incidentally sampled twice during 48 the study. Polyclonality rate is also 2.1x higher than in *P. falciparum*, does not trend positively 49 with estimated incidence, and correlates uniquely to selected demographics. We discuss 50 possible underlying mechanisms and implications for malaria control.

51

#### 52 Introduction

Malaria caused by the parasite *Plasmodium falciparum* is responsible for more than half a
million deaths each year, predominantly in Sub-Saharan Africa and in children under five<sup>1</sup>.
Malaria by *Plasmodium vivax* causes less acute mortality but is more widely distributed at the
global scale<sup>2,3</sup> and likewise causes severe morbidity and socioeconomic impact<sup>1</sup>.

57

58 Progress towards malaria elimination is currently stalling in many endemic regions<sup>4</sup>, and

divergent parasite species' responses to intervention play an important role<sup>5–9</sup>. *P. vivax* in particular often shows stable or increasing incidence during periods in which co-endemic *P. falciparum* is successfully being reduced<sup>4</sup>. It is therefore important to better understand how epidemiological differences between the species affect the impact of control strategies and whether species-tailored approaches are warranted in co-endemic settings.

64 P. falciparum and P. vivax are not closely related (current theory suggests 30-50 million years of independent evolution<sup>10,11</sup>) and differ in key developmental processes and associated clinical 65 66 effects<sup>4</sup>. For both species, human infection begins when sporozoites enter the skin and 67 vasculature during infected anopheline mosquito blood meal. The parasite first infects the liver 68 and later transitions to blood-stage infection where repeated erythrocyte invasion, intra-69 erythrocytic replication, and erythrocyte rupture are associated with febrile and paroxysmal 70 disease. A subset of blood-stage parasites commit to onward transmission by differentiating into 71 the sexual, mosquito-infective gametocyte form. Meiosis occurs after transmission to the 72 mosquito via blood meal and involves outcrossing if genetically distinct gametocytes are present 73 (i.e., if the human infection is polyclonal). The parasite forms oocysts in the mosquito midgut 74 and then sporozoites, which accumulate in the mosquito salivary glands<sup>12</sup>.

75 P. vivax behaves distinctly within the human stages of this infection cycle in multiple key 76 aspects. First, not all P. vivax parasites that successfully reach the liver immediately begin 77 schizogony, a process which begins immediately in all liver-stage *P. falciparum* parasites. 78 Rather, a subset of liver-stage *P. vivax* parasites form a dormant hypnozoite reservoir, which 79 can initiate additional blood-stage infections weeks to months after initial infection<sup>13</sup>. Clearing 80 this relapsing hypnozoite reservoir from the liver is hindered by incomplete drug efficacy<sup>14</sup>, 81 toxicity<sup>15</sup>, and adherence concerns<sup>16</sup>. In the blood stage, *P. vivax* invades a smaller subset of 82 erythrocytes<sup>17</sup> and thus more frequently creates submicroscopic infections, especially in 83 adults<sup>18</sup>. P. vivax also develops transmissible gametocytes approximately one week earlier than

*P. falciparum*. This increases the likelihood of onward transmission before antimalarial treatment
 occurs<sup>19,20</sup>. Several experimental infection studies have additionally suggested that the minimum
 gametocyte density required to infect susceptible mosquitoes is intrinsically lower in *P. vivax* than in P. *falciparum*<sup>19,21-25</sup>.

88 Taken together, the above properties are thought to make P. *vivax* more resilient to clinical

interventions targeting symptomatic pediatric infection, a main focus of *P. falciparum* control.

90 Vector control measures are also thought to have weaker or delayed effects on *P. vivax* due to

91 post-intervention relapse from undetected or unsuccessfully cleared hypnozoite reservoirs, and

92 higher probability to achieve onward transmission when mosquito abundance is low.

93 Furthermore, long-lasting hypnozoite reservoirs and more transmissible asymptomatic blood-

94 stage infections may make *P. vivax* more effective at long-distance dispersal and outcrossing

95 with unrelated strains. This may also include greater potential for allochthonous transmission

96 where malaria was previously absent or cleared<sup>26–28</sup>.

97

The epidemiological effects of these biological differences between *P. falciparum* and *P. vivax* have been difficult to quantify because synchronized comparative study designs that avoid confounding by methodological and spatiotemporal factors are challenging to establish<sup>29</sup>. Study systems representing true species sympatry are also rare, as *P. falciparum* and *P. vivax* often occupy distinct, only partially overlapping socio-geographic partitions within areas more broadly considered co-endemic<sup>2,3</sup>.

This study uniquely couples a spatiotemporally matched genomic sampling scheme with
epidemiological analysis of disaggregated (patient-level) malaria case records to discern coendemic *P. falciparum* and *P. vivax* transmission dynamics. We focus on Guyana, where both
species contribute substantially to the national case count (32.3% *P. falciparum*, 67.4% *P. vivax*,
and <1% *P. malariae* in 2019) and where true sympatry is geographically widespread. Malaria in

Guyana also involves a diverse mix of ethnicities (e.g., strong representation from
Afroguyanese, East Indian, and Amerindian ethnicities) and dynamic population mobility
patterns relating to the mining field. Next to important distinctions relating to geographic and
host demographic variables, we demonstrate clear species contrasts in strain ancestry,
persistence, dispersal, and infection complexity within this multifaceted transmission context.
We discuss possible biological drivers behind divergent species epidemiologies and identify
various implications for intervention.

# 117 **Results**

# 118 General spatiotemporal species prevalence

119 We first conducted a descriptive summary of country-wide passive case detection records made

120 available by the Guyana Ministry of Health (GMOH) for 2006 to 2019. Rolling monthly counts

demonstrate well-balanced case burden between species from 2006 to 2010 followed by higher

122 *P. falciparum* incidence from 2010 to 2013 (Fig. 1a). *P. vivax* cases began to exceed those of *P.* 

123 falciparum in mid-2013 and remained overrepresented until 2019. Individual-level case

metadata have been curated by the GMOH for 2019. We therefore focus on 2019 for most

subsequent epidemiological analyses. 2019 records include 17,710 single-species cases

126 (67.4% *P. vivax*, 32.3% *P. falciparum*, and 0.2% *P. malariae*) and 1,001 mixed-species cases

127 containing both *P. vivax* and *P. falciparum* (Supplementary Table 1). Both species show

transmission throughout the year and elevated incidence between April and August

129 (Supplementary Fig. 1).

# 130 Species intricacies of a wide co-endemic distribution

131 2019 case records show the extent of *P. falciparum – P. vivax* geographic and demographic co-

endemicity in Guyana (Fig. 1b-d). Regions I, VII, and VIII account for 94.6% of *P. falciparum* 

133 cases and 89.3% of *P. vivax* cases, and regional species proportions remain stable across East

134 Indian, Amerindian and Mixed/Other ethnicity groups. While P. vivax consistently predominates 135 in these groups, case majority flips to *P. falciparum* in the Afroguyanese (Chi-squared tests,  $\chi^2$ 136 = 36.13 (I), 269.63 (VII), 125.51 (VIII), p < 0.001 (all regions), Fig. 1b). We further classified 137 infection localities into 27 epidemiological zones (average 3,631 km<sup>2</sup> each) defined using river-138 road transport networks and mobility friction maps (Fig. 1c, Supplementary Fig. 2). Again, 139 species sympatry is consistently maintained in all zones within Regions I, VII, and VIII. The 140 relative proportion of *P. vivax* cases is generally higher outside of this main malaria range, 141 especially to the south in Region IX (e.g., Upper Rupununi and Greater Lethem). Patients aged 142 15 -54 clearly predominate in both species but are more common in *P. falciparum* (84.5%) than 143 in *P. vivax* (79.2% – Chi-squared test,  $\chi^2 = 82.89$ , p < 0.001, Fig. 1d). The proportion of cases 144 representing *P. falciparum* also increases markedly with age in male patients (Kruskal-Wallis 145 test, H = 23.64, p < 0.001 – see post-hoc significance in Fig. 1e). Working-age ( $\geq$ 15 years) to 146 child (<15 years) case ratios are less markedly elevated in Amerindians than in non-Amerindian ethnicities (3.8 to 1 vs. 13.5 to 1, respectively, for *P. falciparum* (Chi-squared test,  $\chi^2 = 273.84$ , 147 p < 0.001) and 2.6 to 1 vs. 7.4 to 1, respectively, for *P. vivax* (Chi-squared test,  $\chi^2 = 515.98$ , p < 100148 149 0.001), Supplementary Fig. 4). Elevated case bias towards non-Amerindian working-age males is consistent with gold mining driving malaria burden in Guyana<sup>30</sup>, especially in non-resident 150 151 (e.g., 'coast lander'<sup>31</sup>) mining groups. Higher working-age to child case ratio for *P. falciparum* vs. 152 P. vivax may also suggest that transmission from mining to non-mining communities, and 153 sustained transmission in non-mining communities, is less common in *P. falciparum* than in *P.* 154 vivax.

# 155 **Deep genomic profiling of each species across 2020 and 2021**

To search for epidemiological features that are not observable from traditional symptomatic
case analysis, we sequenced 708 *P. falciparum* and 762 *P. vivax* genomes from patient blood
spots collected passively by the GMOH. Collection followed informed consent using a study

159 protocol approved by ethical committees of Harvard University and the government of Guyana. Sequencing was successful for 666 P. falciparum and 705 P. vivax genomes (Supplementary 160 161 Table 2) continuously spanning January 2020 to June 2021 (Fig. 2). Of these 1,371 samples, 162 1,216 (89%) are coupled with patient travel history records used to infer geographic infection 163 source (representing Regions I, VII, and VIII in 1,156 (95.1%) samples). We additionally 164 sequenced 7 P. falciparum and 16 P. vivax samples from 2019 representing infections from 165 Venezuela and analyzed two publicly available Venezuelan P. falciparum genomes from 166 2015/16 (European Nucleotide Archive (https://www.ebi.ac.uk) accessions ERR1818176 and 167 ERR2496572).

#### 168 Discrepant genomic diversity and relatedness between species

Genomic analyses focused on 46,067 and 266,141 sites with segregating single-nucleotide polymorphisms (SNPs) identified in the *P. falciparum* and *P. vivax* sample sets (respectively) following quality filtration steps (see Methods). This difference in the number of segregating sites and in average pairwise nucleotide diversity observed within each sample set  $(1.99 \cdot 10^{-4}$ differences per bp in *P. falciparum* and  $2.91 \cdot 10^{-4}$  differences per bp in *P. vivax*, <u>Supplementary</u> Fig. 5) align with previous evidence that genetic diversity is higher in *P. vivax* at the global scale<sup>32</sup>.

176 To further characterize diversity within each sample set, we applied a hidden state model<sup>33</sup> to 177 estimate parasite relatedness due to recent common ancestry (identity-by-descent; IBD) for all 178 monoclonal sample pairs (we excluded 250 samples identified as multi-strain infections using a 179 Bayesian framework<sup>34</sup>). The relatedness distributions (Fig. 3a) clearly differ between the two 180 species (Kolmogorov-Smirnov test, D = 0.99, p < 0.001). Pairwise relatedness values in *P. vivax* 181 exhibit a mean of 0.048, with very little standard deviation (sd = 0.031) and minimal skew or 182 outlier occurrence. These results are indicative of a diverse, frequently outcrossing population 183 without substantial sub-clustering into groups of highly related individuals. In contrast, most

184 pairwise comparisons in *P. falciparum* exhibit greater than half-sibling-level relatedness (mean = 185  $0.310 \pm 0.124$  sd). The broader, right-tailed relatedness distribution also includes a peak near 1 186 representing the presence of identical clones as well as values between 0.5 and 0.75 187 representing the presence of various inbred sibling-level relationships. A network analysis 188 identified 79 clonal groups (>0.90 IBD) among *P. falciparum* samples, represented by 2 to 39 189 members each (Supplementary Fig. 6). Clonal group membership detection was often 190 spatiotemporally aggregated (e.g., >50% of group members detected within 4 months per 191 epidemiological zone, Supplementary Fig. 7), consistent with outbreak-like patterns of 192 prevalence<sup>35</sup>. The largest clonal groups spread across multiple geographic areas 193 (Supplementary Fig. 8a), and most appear highly interrelated (e.g., 50 groups collapse into a 194 single network when re-clustering samples at >0.60 IBD, Supplementary Fig. 6). Four groups 195 noted with asterisks in Supplementary Fig. 6 and mapped in Supplementary Fig. 8b appear 196 slightly divergent (1.7 to 3.3 sd below average between-group IBD). Other clonal patterns 197 mapped in Supplementary Fig. 8b include the clustering of groups #7, #9, and #10 around Port 198 Kaituma and Mabaruma (Region I), groups #18, #24, and #49 along the Mazaruni and Puruni 199 Rivers (Region VII), and groups #27, #32, and #52 around Mahdia and the lower Potaro River 200 (Region 8). Two divergent clonal pairs (#20 and #65) also have partial membership in 201 Venezuela (star symbols in Supplementary Fig. 8b) and likely represent transmission of 202 imported parasite lineages (Supplementary Text 1, Supplementary Fig. 9). Group #20 also 203 represents a case of longer-term clonal persistence from 2015 to 2020. 204 Clonal network analysis results for *P. vivax* are very different. We observe only 29 clonal

205 groups, of which 23 contain 2 members each and 6 contain 3 members each. Post-hoc review 206 of patient-specific case codes (blinded to non-GMOH authors) also clarifies that 11 of 23 clonal 207 pairs represent repeated sampling from the same patient (median time between 1st and 2nd 208 visit = 109 days (minimum = 40 days, maximum = 229 days). These likely represent relapses

registered as new infections prior to genetic analysis. No close relatedness occurs among any clonal groups (the same number of groups created via clustering at >0.90 IBD remains when reclustering at >0.30 IBD) or between Guyanese and Venezuelan sample sets (<u>Supplementary</u> <u>Fig. 6, Supplementary Text 1, Supplementary Fig. 9</u>). Furthermore, clonal persistence in *P. vivax* (average = 79 days, maximum = 243 days) appears more temporally limited (Wilcoxon test, W = 55078, p = 0.003) than in *P. falciparum* (median = 113.5 days, maximum = 500 days, excluding imported lineages (groups #20 and #65), <u>Supplementary Fig. 10</u>).

216

# 217 Regional isolation-by-distance in P. falciparum vs. micrographic structure in P. vivax

218 We next evaluated whether parasite genetic relatedness declines with spatial distance (Fig. 3b). 219 The presence of 'isolation-by-distance' is a common indicator of population structure due to 220 spatially limited dispersal, understanding of which is key to the success of control objectives 221 such as limiting the spread of drug resistance<sup>36,37</sup>. We applied sliding windows of spatial 222 distance, guantifying the fraction of pairwise comparisons in each 30 km window that showed 223 >0.50 IBD. Results for *P. falciparum* demonstrate a linear decrease in the frequency of >0.50 224 IBD as spatial distance increases between sample pairs (Pearson's r = 0.89, p < 0.001). 225 Exceptions occur at window starts near 100 km and 200 km where the frequency of close 226 relatives briefly rebounds to levels observed at shorter distance classes. These upticks may 227 reflect accumulation of relatedness between common travel hubs or mining foci and 228 discontinuous transmission risk during interregional host movement.

229

230 In *P. vivax*, sample pairs with >0.50 IBD were very rare (n = 87) but also clearly

overrepresented in the first spatial distance class (0-30 km, Fig. 3). A continued decline in >0.50

IBD frequency with spatial distance was however not apparent. To help assess whether the

spatial distance across which negative correlation between relatedness and spatial distance

234	persists differs between species, we quantified 99 <sup>th</sup> percentile (p99) IBD, an alternative
235	definition of close ancestry that normalizes statistical power in comparative Mantel tests
236	(Supplementary Fig. 11, top). Correlogram results for <i>P. falciparum</i> indicated significant
237	correlation between genetic distance (1 - p99 IBD frequency) and spatial distance for 0-30 km
238	(Mantel r = 0.49, p = 0.001) as well as for 30-60 km distance classes (Mantel r = 0.19, p =
239	0.017). In <i>P. vivax</i> , correlation between 1 - p99 IBD frequency and spatial distance loses
240	statistical significance at 30-60 km (Mantel r = 0.12, p = 0.089). Shorter isolation-by-distance
241	signal relative to <i>P. falciparum</i> also occurred when using the absolute, >0.50 IBD metric to
242	define close ancestry (Supplementary Fig. 11, bottom).
243	Genetic vs. non-genetic markers accord better on P. falciparum than on P. vivax
244	dispersal
245	We further examined how parasite pairs exhibiting >0.50 IBD were distributed among
246	epidemiological zones (Fig. 4) and whether this parasite genetic structure correlated to patient
247	travel patterns inferred by comparing sites of patient diagnosis and prior stay (2 weeks) in the

epidemiological database from 2019. Examining the extent to which parasite propagation across

specific geographic or administrative units can be tracked and predicted using genetic or

250 traditional case metrics is important in helping determine potential to focus and tailor

251 intervention activities and surveillance data types.

252 Corollary to the clear elevation in >0.50 IBD frequency at 0-30 km (Fig. 3) and significant

isolation-by-distance at 0-30 km (Supplementary Fig. 11) in both *P. falciparum* and *P. vivax*,

both also generally showed highest frequencies of elevated relatedness within (i.e., not

between) epidemiological zones (Fig. 4). This observation from the genomic data matches the

256 observation from the epidemiological database that the majority of symptomatic malaria cases

257 involve non-mobile, 'local' infections (black pie slices, <u>Supplementary Fig. 12</u>), i.e., patients

reporting absence of travel 14 days prior to diagnosis. The epidemiological data also suggest

259 that the proportion of local to nonlocal infections (i.e., cases in which patients reported having 260 stayed in a distinct epidemiological zone 14 days prior to diagnosis) is higher for *P. vivax* than 261 for *P. falciparum* in 16 of 23 analyzed epidemiological zones (Supplementary Fig. 13). These 16 262 zones include non-endemic coastal areas such as Greater Georgetown, where 178 of 1,611 263 (11.0%) P. vivax patients (vs. 45 of 867 (5.2%) P. falciparum patients) reported absence of prior 264 travel (Chi-squared test,  $\chi^2 = 22.915$ , p < 0.001). Elevated pairwise nucleotide diversity 265  $(+20.7\% \pi)$  in *P. vivax* samples attributed to Greater Georgetown (Welch's t test, t = 4.71, p < 266 0.001, Supplementary Fig. 5) further supports the hypothesis that relapses representing various 267 different geographic infection sources are diagnosed in this capital district. 268 269 To statistically compare inference of parasite movement based on genetic vs. epidemiological 270 data types, we correlated the relative frequency of parasite >0.50 IBD and patient travel events 271 ('case flow') among all pairs of endemic epidemiological zones for which patient movement was 272 detected in the epidemiological database (i.e., all arrowed segments in Supplementary Fig. 12). 273 In the case of *P. falciparum*, relative frequencies of >0.50 IBD and case flow were moderately 274 correlated (Pearson's r = 0.44, p = 0.029) between endemic zones (Fig. 5), with most 275 conspicuous congruence in the context of reduced connectivity between Region I and Regions 276 VII and VIII (e.g., see short spokes of elevated >0.50 IBD frequency and intensified case flow 277 around Kaituma and Barima in Region I, yet limited connectivity farther South in Fig. 4 and

278 <u>Supplementary Fig. 12</u>). Only 0.8% of nonlocal infections sampled in Regions VII and VIII (grey

279 pie slices, <u>Supplementary Fig. 12</u>) represented infection sites from Region I. Case flow to

280 Greater Georgetown was also weaker for infections attributed to Region I (36.4%) than for

infections attributed to Region VII (43.4% – Chi-squared test,  $\chi^2 = 48.22$ , p < 0.001) or to

282 Region VIII (74.1% – Chi-squared test,  $\chi^2 = 874.35$ , p < 0.001). These results may in part

reflect the absence of efficient travel routes from Region I to Georgetown (East) and to Regions

farther South. Rivers key to travel in Region I (e.g., the Barima and Barama) lead into a

Northwest delta while those key to travel in Regions VII and VIII (e.g., the Cuyuni and Mazaruni)
flow East into the Essequibo near Georgetown. A handful of semi-developed roads also parallel
and connect areas of the Cuyuni, Mazaruni, and Essequibo in Regions VII and VIII.

288 For *P. vivax*, the frequency of >0.50 IBD also correlated significantly with case flow between

endemic zones (Pearson's r = 0.51, p < 0.001, Fig. 5). Unlike in *P. falciparum*, however,

significance is lost when broadening the classification of elevated relatedness to p99 IBD

291 (Supplementary Fig. 14). This observation helps clarify that the significant relationships detected

when regressing >0.50 IBD frequency on spatial distance (Fig. 3) and case flow (Fig. 5) do not

293 mean that the *P. vivax* population is predictably structured as a whole. Results are instead

consistent with a dispersive, frequently outcrossing *P. vivax* population in which pairwise

relatedness is swiftly erased and local genotype associations are rarely established. In this

scenario, the ephemeral presence of intact clones or sibling-level relatives creates micrographic

spatiotemporal autocorrelations that are not representative of broader population dynamics.

#### Higher outcrossing potential in P. vivax – do relapse and risk carryover play a role?

We further assessed indications from relatedness analyses that outcrossing rate is elevated in *P. vivax* by examining polyclonality rate (i.e., the fraction of samples containing multiple distinct strains) and its variation with respect to geographic and demographic variables. Polyclonality rate is closely related to outcrossing rate because parasite sexual recombination in the mosquito after blood meal only results in outcrossing if multiple distinct strains are ingested simultaneously from the human host.

We observed a polyclonality rate of 24.0% in *P. vivax* vs. 11.4% in *P. falciparum* (Chi-squared test,  $\chi^2 = 36.72$ , p < 0.001, Fig. 6a). Elevated *P. vivax* outcrossing rate implied by this 2.1x polyclonality rate differential helps explain the aforementioned paucity in clonal relationships (Fig. 3) and their limited persistence over time (Supplementary Fig. 10). It is also consistent with

309 the observation that linkage disequilibrium between SNPs declines across physical genetic

310 distance more readily in *P. vivax* than in *P. falciparum* (Supplementary Fig. 15).

311 Polyclonality rate is considered a positive correlate of *P. falciparum* transmission intensity in the 312 absence of high rates of case importation<sup>38</sup>. We assessed this possible relationship in *P*. 313 falciparum and P. vivax (in which polyclonality may additionally occur via hypnozoite-based 314 relapse) by plotting polyclonality rates per epidemiological zone against corresponding 315 incidence estimates (Fig. 6b, see Methods). Interestingly, P. vivax polyclonality rates remain 316 consistently inflated, regardless of incidence estimate. Polyclonality rate and incidence 317 estimates also trend in opposite directions for *P. falciparum* vs. *P. vivax*, though neither 318 achieves statistical significance. Polyclonality rate was highest in *P. vivax* infections from the 319 Lower Essequibo zone, a key area of travel convergence from the hinterlands of Region VII but 320 one in which malaria risk is not considered high. These results may indicate that P. vivax 321 samples from areas of lower endemicity are more likely to represent imported cases (possibly in 322 the form of relapse) that involve multiple accumulated strains.

323 To further understand polyclonality rate relationships to transmission risk, we compared 324 polyclonality rates in  $\geq$ 15 year-old male and females within the three neighborhood councils 325 (NDCs) containing  $\geq$ 20 genomic samples for each of these groups (Fig. 6c). Males represented 326 the majority of epidemiological case records in the three NDCs, suggesting that transmission 327 risk is generally higher in male-associated occupations. Polyclonality rate in *P. falciparum* thus 328 followed expectations in that observed values appeared consistently higher in males than in 329 females. Polyclonality rates in *P. vivax* were generally more variable (see confidence intervals, 330 especially in females (Fig. 6c)), and were higher in females than in males in NDC VII-2, an area 331 that contains Mahdia and various popular mining sites (e.g., the Mazaruni River Quarry and the 332 Karouni Project). Interestingly, this trend was driven by polyclonality rate enrichment in females among patients reporting Venezuelan nationality (Chi-squared test,  $\chi^2 = 4.33$ , p = 0.037, 333

<u>Supplementary Fig. 16</u>), possibly because infection risk is enhanced in female-biased
 occupations that accompany the active mining sector (e.g., in rest/supply areas where frequent
 contact among gametocyte-carrying male miners, mosquitoes, and female non-miners occurs).
 Enhanced *P. vivax* transmissibility, e.g., due to presymptomatic gametocytemia, may heighten
 this risk.

#### 339 Discussion

In this study we coupled comparative malaria parasite population genomics with passive case
record metadata analyses to compare co-endemic *P. falciparum* and *P. vivax* epidemiology in
Guyana. We observed several key genomic epidemiological contrasts that indicate the need to
consider species-specific approaches to malaria intervention.

344 Most notably, we observed dramatically different patterns of genomic relatedness between the 345 two species. The *P. falciparum* sample set exhibited a relatively broad pairwise IBD distribution 346 centered near values expected for half-sibling-level relatedness, whereas in P. vivax this 347 distribution was less variable and clearly shifted towards zero (6.4x lower average IBD). Clonal 348 pairwise relationships (>0.90 IBD) were detected >50x more often in *P. falciparum* and most 349 clonal *P. falciparum* groups exceeded 3 samples in membership size (max. 38). Many of these 350 groups also displayed spatiotemporally aggregated, outbreak-like patterns of detection. In P. 351 vivax, clonal groups had no more than 2-3 members and appeared to persist for shorter periods 352 of time; many clonal *P. falciparum* relationships were detected between samples separated by 353 >12 months whereas for *P. vivax* the maximum time between clone detection was 243 days.

This strong contrast in relatedness structure may derive mechanistically from polyclonality rate differences between the species. Polyclonality rate is a key determinant of the extent to which clones and near-relatives can persist in transmission cycles because polyclonality is a prerequisite to sexual recombination between distinct strains (outcrossing) in the mosquito

stage. In this study, *P. vivax* polyclonality was not only 2.1x higher than in *P. falciparum* at the
population level, but also remained consistently inflated when accounting for estimated
incidence in subgeographic comparisons. This result suggests that elevated polyclonality rates
in *P. vivax* are not a product of higher infection incidence alone. *P. vivax* relapse from the
dormant hyponozite liver stage likely represents an additional source of polyclonality because
relapse can overlap with current infection and can involve the successive activation of divergent
strains<sup>39</sup>.

365 Importantly, though humans are the common agent of dispersal throughout Guyana for both 366 parasite species, we observed highly contrasting patterns of spatial genetic structure. The 367 frequency of close *P. falciparum* relatives (>0.50 IBD) decayed with geographic distance, and 368 selected clonal genotypes could be linked to specific geographic subdivisions in Guyana. In P. 369 vivax, significant correlation of relatedness with spatial distance did not occur among sample 370 pairs separated by >30 km, and meaningful regional population structure could not be resolved. 371 Limited macrographic structure in *P. vivax* may occur largely because the dormant hypnozoite 372 liver stage unique to this species facilitates long-distance dispersal via relapse in mobile hosts. 373 Various study results point to the influence of relapse on *P. vivax* dispersal in the study region. 374 At health centers in Greater Georgetown, for example, an absence of travel 14 days prior to 375 diagnosis was reported more than twice as frequently by P. vivax patients (178 of 1,611 376 (11.0%)) than by *P. falciparum* patients (45 of 867 (5.2%)). Nucleotide diversity was also 377 significantly elevated in *P. vivax* samples representing such non-traveler cases. Given that 378 Greater Georgetown is considered free of malaria transmission, many non-traveler P. vivax 379 cases may represent reactivation of dormant parasite diversity that has accumulated in hosts 380 over longer periods of time<sup>39</sup>. We also observed the recurrence of *P. vivax* clones in 11 patients 381 for which blood spots were sequenced from separate malaria visits. These same-patient sample 382 pairs represented symptomatic malaria episodes separated by a median of 109 days and the

prescription of a 3-day Chloroquine + 14-day primaquine treatment course. They may thus not
 only represent direct evidence of relapse but also point to efficacy and adherence challenges
 relating to hypnozoicidal drugs.

386

Together, these observations suggest that differences in underlying parasite biology are
 contributing to divergent species responses to intervention, including flips from *P. falciparum* to
 *P. vivax* case majority observed over the last 15 years in regions nearing elimination goals (e.g.,
 Guyana, Solomon islands, Myanmar, Cambodia, Lao PDR<sup>1</sup>).

391 In the case of *P. falciparum* in Guyana, malaria control strategy may benefit from further 392 advancing decentralized case management and differentiating resource allocation based on 393 real-time spatiotemporal surveillance. Similar to regions in Southeast Asia where these 394 approaches have recently reduced *P. falciparum* cases to historic lows<sup>40</sup>, our study indicated a 395 *P. falciparum* metapopulation maintained by periodic expansions from high-risk transmission 396 areas (mines in remote riparian forest) where infrastructure is limited and occupational 397 incentives conflict with self-care. In these settings, treatment-seeking is more likely to be 398 delayed (increasing the risk of transmission prior to treatment) and access to regional treatment 399 centers may involve long-distance travel through endemic terrain. It therefore may be beneficial 400 to further decentralize medical capacity from regional treatment centers to localities with strong 401 outbreak signals (e.g., Puruni Landing) or to strategic points along travel routes that may 402 facilitate parasite dispersal (e.g., along the Mazaruni River, a possible conduit for clonal P. 403 falciparum dispersal based on this study). Self-administered diagnostic and treatment 404 approaches (e.g., Malakit<sup>41</sup>) might additionally help cover remote areas, with monitoring to 405 evaluate the extent to which incorrect self-treatment may negatively impact user health or 406 contribute to resistance emergence.

407 In the case of *P. vivax* control, our study suggests that similar strategies of decentralized and focally intensified intervention will be less efficacious. We do not observe tractable 408 409 metapopulation structure that would help prioritize intervention foci, and various results point to 410 the risk of latent dispersal processes undermining geographically differentiated intervention. 411 Decentralizing treatment resources, especially the integration of unsupervised treatment kits, 412 also appear less tractable due to the greater complexity of safe and effective 'radical' P. vivax 413 cure (treatment targeting both bloodstage and hypnozoite parasites). Hypnozoite clearance 414 generally involves two-week treatment with 8-aminoquinolone drugs and requires prior glucose-415 6-phosphate dehydrogenase (G6PD) deficiency assessment of haemolysis risk<sup>15</sup>. This also 416 makes conventional mass drug administration approaches targeting latent *P. vivax* reservoirs 417 difficult to realize in settings without exceptionally low rates of G6PD deficiency<sup>42</sup> and 418 exceptionally consistent treatment compliance<sup>43</sup>. It is therefore necessary to advance work on 419 alternative implementation strategies (e.g., CUREMA<sup>44</sup> approaches to radical cure in medically 420 underserved populations of the Guiana Shield) and towards the discovery of new hypnozoicidal 421 drugs.

In the interim, fortifying preventive vector control and risk awareness programs is also important.
A recent study suggests that increased risk perception is associated with increased preventive
behavior against vector borne disease in Guyana, although effect size is small (4-5%)<sup>45</sup>. Effect
size might be increased if educational programs more strongly convey risk of onward malaria
transmission as opposed to risk solely towards personal health. Such altruistic risk perception
may be relevant to the more rapid, pre-symptomatic spread of *P. vivax* malaria into local
vectors, including upon miner return to non-mining home environments.

This study had several limitations. Importantly, the near-relative detection approach we used to
describe parasite population structure focuses on outlier IBD relationships and therefore
underuses available sequence content. We also did not infer IBD relationships involving

432 polyclonal infections, which constituted 17.9% of our genomic sample set. Furthermore, 433 genomic sample collection relied on a sentinel method which may bias against parasite diversity 434 found in remote, disconnected transmission cycles (e.g., Amerindian settlements). It was also 435 challenging to address the transitory nature of human settlement in the hinterlands of Guyana, 436 where conventional population sizes are not recorded or do not apply. This primarily 437 complicated the estimation of zonal incidence and its relationship to polyclonality rates. High 438 host mobility in undercharted hinterland areas also added uncertainty to geographic infection 439 source estimates.

440 Despite these limitations, this study clearly exposes the discrepant profiles of co-endemic *P*.

441 *falciparum* and *P. vivax* malaria in a low transmission setting, and emphasizes the need for

distinct intervention and surveillance approaches in order to succeed in eliminating both

443 species. The current disproportionate investment in drugs, vaccines, and monoclonal antibodies

for *P. falciparum* increases the likelihood that *P. vivax* will persist in many co-endemic regions
after *P. falciparum* is eliminated, forestalling the ultimate goal of eliminating malaria from all
regions and demographics.

#### 447 Methods

# 448 *Epidemiological database and definitions/categorizations*

449 The epidemiological database analyzed in this study comprised all malaria episodes detected in 450 Guyana via passive surveillance (estimated to represent approximately 80% of cases<sup>1</sup>) and 451 reported to the National Malaria Program between 2007 and 2019. Malaria episodes were 452 defined using both medical diagnoses and parasitological tests (blood microscopy, and less 453 commonly, rapid diagnostic tests). Patient records were curated by the Vector Control Services 454 (VCS) division of the GMOH and anonymized records of patient age, gender, nationality, and 455 self-reported ethnicity (categorized as "Afroguyanese", "Amerindian", "East Indian", "Chinese", 456 "Portuguese", "European", "Mixed", or "Other") were provided to the Harvard T.H. Chan School

457 of Public Health (HSPH) following approval by the Harvard University Area Human Research 458 Protection Program (protocol IRB18-1638) and by ethical committees of the GMOH. Infection 459 localities were inferred based on voluntary responses about "Where [the] patient stayed 2 460 weeks ago" (see survey form in Supplementary Fig. 17). Each travel history response was 461 classified to one of 460 country-wide localities with known latitude/longitude coordinates. 462 463 To define epidemiological zones, we mapped malaria survey sites used by the GMOH 464 (https://gazetteer.glsc.gov.gy/gazetteer/#7/3.650/-57.129) onto a custom shape file containing 465 Guyana's primary river and road coordinates and onto a motorized transport resistance raster 466 obtained from https://malariaatlas.org/ (Supplementary Fig. 2). Sites were clustered based on river/road connectivity in the R package RIVERDIST<sup>46</sup> v0.16.3, travel conductance using the R 467 468 package GDISTANCE<sup>47</sup> v1.6.4, and manual assessment of river/road and resistance layers in 469 QGIS<sup>48</sup> v2.18.4. Transmission intensity was estimated for each epidemiological zone using population size estimates from the LandScan Project<sup>49</sup>. The LandScan approach uses 470 471 dasymetric modeling to disaggregate census counts based on remotely sensed images<sup>49</sup>. We 472 used Landscan Global 2019 data to estimate average population density within 10 arcmin (ca. 473 20 km) of the centroid representing all localities contributing malaria cases within an 474 epidemiological zone. We then divided the zonal case count by its LandScan population density 475 estimate.

# 476 Clinical sample material, sequencing, and variant calling

Following informed consent to analyze parasite genetic polymorphism using patient blood,
samples were collected from microscopy or RDT-positive patients by spotting approximately 50200 µl whole blood onto Whatman FTA filter paper cards. Collection was carried out by VCS
between January 2020 and June 2021 at medical facilities in Bartica, Georgetown, Mahdia,
Lethem, and Port Kaituma, Guyana. Samples were stored at room temperature using individual

desiccant packets before shipment to HSPH. The same anonymized patient metadata variables as described in the previous section (<u>Supplementary Fig. 17</u>) were also provided to HSPH. An additional 23 dried blood spot samples were collected in Venezuela at the Institute of Tropical Medicine, Central University of Venezuela (Caracas, bioethics permit CEC-IMT 12/2013) and Biomedical Research and Therapeutic Vaccines Institute (Ciudad Bolívar, bioethics permit CHURPCBBS-008-2019) in 2019. Metadata for these samples (collection date and reported place of stay (municipality) two weeks prior to diagnosis) was likewise de-identified prior to

489 HSPH access (<u>Supplementary Table 2</u>).

490 We extracted total genomic DNA from dried blood spot samples (approximately 20-35 mm<sup>2</sup>) 491 spotted area punched per sample) using KingFisher Ready DNA Ultra 2.0 Prefilled Plates on 492 the Kingfisher Flex instrument (ThermoFisher Scientific). We subsequently applied whole-493 genome amplification to DNA extracts using sets of ten *P. falciparum<sup>50</sup>* and/or *P. vivax*-selective 494 oligos<sup>44</sup> (set selection based on previous microscopy or RDT-based species assignment) and 495 used AMPure XP magnetic beads (Beckman Coulter) to exchange post-reaction sample buffer 496 to 10 mM Tris-HCI + 0.1 mM EDTA. Final library construction using the NEBNext Ultra II FS 497 DNA Library Prep Kit (NEB #E6177) and 2 x 150 bp sequencing on the Illumina HiSeqX 498 platform (150-bp paired-end reads) was completed at the Broad Institute. We aligned reads to 499 the *P. falciparum* 3D7 and *P. vivax* PvP01 reference genome assemblies using BWA-MEM<sup>52</sup> 500 and called SNPs and INDELs using GATK<sup>53</sup> v3.5-0-g36282e4 'HaplotypeCaller' and 501 'GenotypeGVCFs' according to best practices defined by the Pf3k consortium 502 (http://www.malariagen.net/data\_package/pf3k-5/). The mapping and joint variant call process 503 also included sample accessions ERR1818176 and ERR2496572 representing malaria 504 infections from Venezuela (further geographic specifics unknown). All downstream genetic analysis focused on SNP sites in core regions of the genome<sup>54,55</sup> and >5 bp from any INDEL 505

call. The base SNP call set created for each species also excluded sites at which >7.5% of
monoclonal samples showed multi-allelic ('heterozygous') calls.

# 508 Parasite genetic analyses

509 We assessed polyclonality using THEREALMcCOIL<sup>34</sup> v2, a Bayesian Markov chain Monte Carlo 510 approach that simultaneously estimates population allele frequency for each SNP and COI for 511 each individual in the sample set. We applied the categorical method (classifying SNP calls 512 binarily as homozygous or heterozygous regardless of the signal intensity of each component 513 allele) to bi-allelic SNP sites with  $\geq$ 10% minor allele frequency and  $\geq$ 90% call success across 514 samples. We further subsampled input to limit computational costs. Subsampling using the '--515 thin' function in VCFtools<sup>56</sup> v0.1.15 resulted in 337 *P. falciparum* and 350 *P. vivax* input sites. 516 We kept input parameters in default and used the lower bound (quantile = 2.5%) output value as 517 a conservative estimate of sample COI.

518

Analyses of genetic diversity and relatedness only included monoclonal samples. We estimated
nucleotide diversity from the base SNP call sets (previous section) by measuring average
nucleotide differences over discrete 100 kbp windows (no overlap) with VCFtools<sup>56</sup> v0.1.15. We
measured linkage decay over bi-allelic SNP sites by recoding calls to non-reference allele
counts (0, 1, or 2) and computing linkage (r<sup>2</sup>) in sliding 10 kbp windows (200 bp steps) in
PLINK<sup>57</sup> v1.90b1g.

525 We estimated genetic relatedness between samples based on the concept of IBD. Unlike 526 identity by state (IBS), IBD specifically represents genetic similarity inferred to have been 527 inherited from a common ancestor based on factors affecting linkage likelihood such as 528 population allele frequency, recombination rate, and chromosomal distances between variant 529 sites. IBD generally enhances representation of recent ancestry in obligately sexual species in 530 which divergence history is influenced more strongly by recombination than by the individual

accumulation of point mutation events. We ran hmmIBD<sup>33</sup> in default settings to estimate
population allele frequency and infer presence or absence of IBD at all bi-allelic SNPs with ≥2%
minor allele frequency and ≥70% call success across samples. We used the fraction of all
variant sites inferred as IBD ('fract\_sites\_IBD') to summarize relatedness for each sample pair.
We used the R package IGRAPH<sup>58</sup> v1.3.5 to generate connected graphs (clusters) in which
edges represent sample pairs with relatedness values above a specified threshold. Clusters

537 therefore represent groups of samples (nodes) in which each sample is connected by at least

538 one direct edge to another sample (but simultaneous direct connections to additional cluster

539 members are not required).

540 We also correlated relatedness values to Euclidean distances calculated from latitude and 541 longitude (WGS 84) coordinates projected onto a common xy plane (EPSG 3786). We used 542 Mantel tests to assess statistical significance between genetic and spatial distance matrices 543 using the R package VEGAN<sup>59</sup> v2.6-4. We applied repeated random draws of 10 samples from 544 each epidemiological zone (drawing until depletion without replacement) to build each distance 545 matrix. We also mapped the frequency of pairwise relatedness between epidemiological zones 546 using shape files from the Natural Earth public domain map dataset<sup>60</sup>.

547 Finally, we also assessed the possibility that cases of clonal IBD detection in *P. vivax* represent 548 repeated blood spot sampling events from the same patient (e.g., a first clinical visit due to 549 primary infection and one or more later clinical visits due to relapse or recrudescence by the 550 same parasite genotype). HSPH authors sent a guery list of 705 P. vivax samples to the GMOH 551 and the GMOH flagged each according to whether it represents a patient which is also 552 represented by another sample in the query list. The list returned by the GMOH indicated 1x 553 (i.e., non-repeat) patient representation for 589 samples, 2x patient representation for 92 554 samples (necessarily representing 46 patients) and  $\geq 3x$  patient representation for 22 samples

- (necessarily representing ≤7 patients). The returned list did not specify which sample sets
  corresponded to the same patient.
- 557
- 558

# 559 Main figure legends

- 560 Fig. 1 Spatiotemporal and demographic patterns of *P. falciparum* and *P. vivax* in Guyana.
- **a)** Weekly reported cases (points) and 30-days rolling average (line) between 2006 and 2019.
- b) Percent of cases representing *P. falciparum* (% Pf) by region and ethnicity in 2019. Asterisks
- 563 indicate significant differences in % Pf between Afroguyanese and non-Afroguyanese cases in
- each region ( $\chi^2$ -test). **c)** Cumulative case count in epidemiological zones with >500 total cases
- 565 in 2019. Zones on the y-axis are ordered by *P. vivax* case count (descending from top to
- bottom). d) Case counts by gender and age in 2019. e) % Pf by gender and age in 2019.
- 567 Asterisks indicate significant differences between age groups (Dunn test).

#### 568 Fig. 2 Spatiotemporally matched *P. falciparum* and *P. vivax* sampling in Guyana. Colors in

- the map and histograms represent the neighborhood councils (NDCs) to which infections from
- 570 2020-21 were attributed based on patient response about location of stay 14 days prior to
- 571 diagnosis. NDCs within Regions I, VII, and VIII are labeled in the map.

# 572 Fig. 3 Pairwise IBD and relationships to spatial distance in *P. falciparum* and *P. vivax* in

- 573 **Guyana. a)** Histogram of pairwise IBD in 2020-21. The y-axis is log10-scaled to help display
- 574 less frequent close-relative observations. Dashed lines indicate species medians. b)
- 575 Relationship of spatial distance between inferred infection sites and the frequency of >0.50 IBD
- 576 in 2020-21. Windowed calculation using step size = 10 km and starting at 0-30 km. Error bars
- 577 represent 90% confidence intervals from bootstrapping 1000x. The model y = a \* e^(-b \* x) + c

was used to fit regression lines of linear and logarithmic shape. Clonal *P. falciparum* groups
represented by ≥10 members are excluded from distance analyses.

# 580 Fig. 4 Frequency of >0.50 IBD within and between epidemiological zones in *P. falciparum*

581 and *P. vivax* in Guyana. Nodes indicate epidemiological zones. Node and segment colors

582 indicate frequency of >0.50 IBD within and between epidemiological zones (respectively) in

583 2020-21. Node sizes are proportional to genomic sampling size. Between-zone comparisons

584 represented by  $\leq$ 50 comparisons are excluded.

# 585 Fig. 5 Relationship between patient case flow and the relative frequency of >0.50 IBD in

586 *P. falciparum* and *P. vivax* in Guyana. Genetic data (y-axis) represents 2020-21 and

587 epidemiological (case flow) data (x-axis) represents 2019. Point color indicates the spatial distance

separating the zones being compared. Comparisons represented by ≤50 comparisons

589 excluded. Grey shading indicates 95% confidence intervals predicted by linear regression

590 (dashed line). Labeled points represent 1) Central Coast (CC) to Lower Cuyuni (LC), 2) Head

591 Waini (HW) to Kaituma and Barima (KB), 3) Lower Potaro (LP) to Mid Essequibo, 4) KB to

592 Waini, 5) CC to Lower Mazaruni (LM), 6) KB to North Delta (ND), 7) LC to LM, 8) Head

593 Mazaruni to LM, 9) Cristinas Border to LM, 10) LM to Mid Mazaruni and Issano Rd, 11) LM to

594 Upper Cuyuni, 12) CC to KB, 13) LM to ND, 14) East of Georgetown to LP, 15) LM to Upper

595 Rupununi (UR), 16) LP to UR, 17) Greater Lethem to LM, and 18) LM to LP.

#### 596 Fig. 6 Polyclonality rates and relationships to estimated incidence and patient gender in

597 *P. falciparum* and *P. vivax* in Guyana. a) Complexity of infection (COI) values in 2020-21,

598 population-wide. b) Polyclonality rate (2020-21) vs. estimated incidence (2019) in

599 epidemiological zones represented by  $\geq$  20 genomic samples (Kaituma\_and\_Barima (1),

600 Lower\_Cuyuni (2), Lower\_Essequibo (3), Lower\_Mazaruni (4), Lower\_Potaro (5),

Mid\_Essequibo (6), Mid\_Mazaruni\_and\_Issano\_Rd (7), Upper\_Cuyuni (8), Upper\_Mazaruni (9),

Greater\_GT (10)). Error bars represent 95% confidence intervals from bootstrapping 100x. c)
Polyclonality rate (2020-21) vs. patient gender in neighborhood district councils (NDCs)
represented by ≥20 genomic samples. Error bars represent 90% confidence intervals from
bootstrapping 1000x.

#### 606 Acknowledgements

- 607 We thank the participants who contributed blood samples to the study, as well as the
- 608 technicians who collected and processed the samples. This study was supported by the Bill &
- 609 Melinda Gates Foundation (INV-009416). Under the grant conditions of the Foundation, a
- 610 Creative Commons Attribution 4.0 Generic License has been assigned to the Author Accepted
- 611 Manuscript version that might arise from this submission. This study was also supported with
- 612 federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of
- 613 Health, Department of Health and Human Services, under Grant Number U19AI110818 to the
- 614 Broad Institute. Sampling in Venezuela was additionally supported by the Scottish Funding
- 615 Council Global Challenges Research Fund (GCRF) Small Grants Fund SFC/AN/12/2017 and
- 616 the GCRF Vector-borne Disease Control Network (EP/T003782/1).

# 617 Data Availability Statement

- 618 The sequence data generated by this study have been deposited in the NCBI Sequence Read
- 619 Archive under BioProject PRJNA809659.
- 620
- 621
- 622

623

# 624 **References**

625

626 1. World Health Organization. WHO malaria report 2023 (WHO, 2023).

Weiss, D. J. et al. Mapping the global prevalence, incidence, and mortality of *Plasmodium falciparum*, 2000-17: a spatial and temporal modelling study. Lancet Lond. Engl. 394, 322–331
 (2019).

- Battle, K. E. et al. Mapping the global endemicity and clinical burden of *Plasmodium vivax*,
  2000-17: a spatial and temporal modelling study. Lancet Lond. Engl. 394, 332–343 (2019).
- 4. Price, R. N., Commons, R. J., Battle, K. E., Thriemer, K. & Mendis, K. *Plasmodium vivax* in the era of the shrinking *P. falciparum* map. Trends Parasitol. 36, 560–570 (2020).
- 5. Oliveira-Ferreira, J. et al. Malaria in Brazil: an overview. Malar. J. 9, 115 (2010).
- 6. Rosas-Aguirre, A. et al. Epidemiology of *Plasmodium vivax* malaria in Peru. Am. J. Trop.
  636 Med. Hyg. 95, 133–144 (2016).
- 637 7. Sattabongkot, J., Tsuboi, T., Zollner, G. E., Sirichaisinthop, J. & Cui, L. *Plasmodium vivax*638 transmission: chances for control? Trends Parasitol. 20, 192–198 (2004).
- 639 8. Sattabongkot, J. et al. Malaria research for tailored control and elimination strategies in the 640 Greater Mekong Subregion. Am. J. Trop. Med. Hyg. 107, 152–159 (2022).
- 641 9. Kenangalem, E. et al. Malaria morbidity and mortality following introduction of a universal
  642 policy of artemisinin-based treatment for malaria in Papua, Indonesia: a longitudinal surveillance
  643 study. PLoS Med. 16, e100281510 (2019).
- 644 10. Sharp, P. M., Plenderleith, L. J. & Hahn, B. H. Ape origins of human malaria. Annu. Rev.
  645 Microbiol. 74, 39–63 (2020).
- 646 11. Cepeda, A. S. et al. The genome of *Plasmodium gonderi*: insights into the evolution of 647 human malaria parasites. Genome Biol. Evol. 16, evae027 (2024).
- 648 12. Cowman, A. F., Healer, J., Marapana, D. & Marsh, K. Malaria: biology and disease. Cell
  649 167, 610–624 (2016).
- Krotoski, W. A. et al. Demonstration of hypnozoites in sporozoite-transmitted *Plasmodium*vivax infection. Am. J. Trop. Med. Hyg. 31, 1291–1293 (1982).
- 14. Llanos-Cuentas, A. et al. Tafenoquine versus primaquine to prevent relapse of *Plasmodium vivax* malaria. N. Engl. J. Med. 380, 229–241 (2019).
- Recht, J., Ashley, E. A. & White, N. J. Use of primaquine and glucose-6-phosphate
   dehydrogenase deficiency testing: divergent policies and practices in malaria endemic
- 656 countries. PLoS Negl. Trop. Dis. 12, e0006230 (2018).

657 16. Bruxvoort, K., Goodman, C., Kachur, S. P. & Schellenberg, D. How patients take malaria
658 treatment: a systematic review of the literature on adherence to antimalarial drugs. PloS One 9,
659 e84555 (2014).

- 660 17. Craik, R. A note on the erythrocytes in malaria. The Lancet 195, 1110 (1920).
- 661 18. Cheng, Q., Cunningham, J. & Gatton, M. L. Systematic review of sub-microscopic *P. vivax* 662 infections: prevalence and determining factors. PLoS Negl. Trop. Dis. 9, e3413 (2015).
- 663 19. Boyd, M. F. & Kitchen, S. F. On the infectiousness of patients infected with *Plasmodium* 664 *vivax* and *Plasmodium falciparum*. Am. J. Trop. Med. Hyg. s1-17, 253–262 (1937).
- 665 20. Wernsdorfer, W. H. Malaria: Principles and practice of malariology. (Edinburgh; New York,666 1988).
- 667 21. Boyd, M. F., Stratman-Thomas, W. K. & Kitchen, S. F. On the relative susceptibility of
  668 *Anopheles quadrimaculatus* to *Plasmodium vivax* and *Plasmodium falciparum*. Am. J. Trop.
  669 Med. Hyg. s1-15, 485–493 (1935).
- 670 22. Boyd, M. F., Stratman-Thomas, W. K. & Muench, H. The occurrence of gametocytes of 671 *Plasmodium vivax* during the primary attack. Am. J. Trop. Med. Hyg. s1-16, 133–138 (1936).
- 672 23. Pukrittayakamee, S. et al. Effects of different antimalarial drugs on gametocyte carriage in 673 *P. vivax* malaria. Am. J. Trop. Med. Hyg. 79, 378–384 (2008).
- 674 24. Galinski, M. R., Meyer, E. V. S. & Barnwell, J. W. Chapter one *Plasmodium vivax*: modern
  675 strategies to study a persistent parasite's life cycle. In: Advances in parasitology (eds. Hay, S. I.,
  676 Price, R. & Baird, J. K.) vol. 81 1–26 (Academic Press, 2013).
- 677 25. Timinao, L. et al. Infectivity of symptomatic malaria patients to *Anopheles farauti* colony
  678 mosquitoes in Papua New Guinea. Front. Cell. Infect. Microbiol. 11, 771233 (2021).
- 679 26. Blackburn, D. et al. Outbreak of locally acquired mosquito-transmitted (autochthonous)
  680 malaria Florida and Texas, May–July 2023. Morb. Mortal. Wkly. Rep. 72, 973–978 (2023).
- 681 27. Danis, K. et al. Malaria in Greece: historical and current reflections on a re-emerging vector
  682 borne disease. Travel Med. Infect. Dis. 11, 8–14 (2013).
- 683 28. Bahk, Y. Y. et al. Epidemiological characteristics of re-emerging *vivax* malaria in the 684 Republic of Korea (1993–2017). Korean J. Parasitol. 56, 531–543 (2018).
- 29. Lopez, L. & Koepfli, C. Systematic review of *Plasmodium falciparum* and *Plasmodium vivax*polyclonal infections: impact of prevalence, study population characteristics, and laboratory
  procedures. PLoS One 16, e0249382 (2021).
- 30. De Salazar, P. M., Cox, H., Imhoff, H., Alexandre, J. S. F. & Buckee, C. O. The association
  between gold mining and malaria in Guyana: a statistical inference and time-series analysis.
  Lancet Planet. Health 5, e731–e738 (2021).
- 31. Hilson, G. & Laing, T. Gold mining, indigenous land claims and conflict in Guyana's
  hinterland. J. Rural Stud. 50, 172–187 (2017).
- 693 32. Neafsey, D. E. et al. The malaria parasite *Plasmodium vivax* exhibits greater genetic 694 diversity than *Plasmodium falciparum*. Nat. Genet. 44, 1046-1050 (2012).

- 695 33. Schaffner, D. F., Taylor, A. R., Wong W., Wirth D. F. & Neafsey D. E. hmmIBD: software to 696 infer pairwise identity by descent between haploid genotypes Malar. J. 17, 196 (2018).
- 697 34. Chang, H.-H. et al. THE REAL McCOIL: a method for the concurrent estimation of the
  698 complexity of infection and SNP allele frequency for malaria parasites. PLoS Comput. Biol. 13,
  699 (2017).
- 35. Vanhove, M. et al. Temporal and spatial dynamics of *Plasmodium falciparum* clonal
  lineages in Guyana. Preprint at https://doi.org/10.1101/2024.01.31.578156 (2024).
- 36. Hubbard, A. et al. Implementing landscape genetics in molecular epidemiology to determine
   drivers of vector-borne disease: a malaria case study. Mol. Ecol. 32, 1848–1859 (2023).
- 37. Verity, R. et al. The impact of antimalarial resistance on the genetic structure of *Plasmodium falciparum* in the DRC. Nat. Commun. 11, 2107 (2020).
- 38. Tessema, S. et al. Using parasite genetic and human mobility data to infer local and cross border malaria connectivity in Southern Africa. eLife 8, e43510 (2019).
- 39. Popovici, J. et al. Genomic analyses reveal the common occurrence and complexity of
   *Plasmodium vivax* relapses in Cambodia. mBio 9, 10.1128/mbio.01888-17 (2018).
- 40. Manzoni, G. et al. Progress towards malaria elimination in the Greater Mekong Subregion:
  perspectives from the World Health Organization. Malar. J. 23, 64 (2024).
- 41. Douine, M. et al. Malakit: an innovative pilot project to self-diagnose and self-treat malaria
  among illegal gold miners in the Guiana Shield. Malar. J. 17, 158 (2018).
- 42. Thaeler, A. D., Arnold, J. & Alving, A. S. A clinical study of primaquine (S. N. 13,272) in the
  treatment of malaria among the Miskito Indians of Nicaragua. Am. J. Trop. Med. Hyg. 2, 989–
  999 (1953).
- 43. Kondrashin, A. et al. Mass primaquine treatment to eliminate vivax malaria: lessons from thepast. Malar. J. 13, 51 (2014).
- 44. Sanna, A. et al. CUREMA project: a further step towards malaria elimination among hard-toreach and mobile populations. Preprint at https://doi.org/10.21203/rs.3.rs-4095394/v1 (2024).
- 45. Lopes-Rafegas, I., Cox, H., Mora, T. & Sicuri, E. The contribution of risk perception and
  social norms to reported preventive behaviour against selected vector-borne diseases in
  Guyana. Sci. Rep. 13, 16866 (2023).
- 46. Tyers, M. riverdist: river network distance computation and applications. R Package version0.16.3 (2024).
- 47. van Etten, J., de Sousa, K., & Marx, A. gdistance: distances and routes on geographical
  grids. R Package version 1.6.4 (2023).
- 48. QGIS Development Team. Open Source Geospatial Foundation. Software version 2.18.4(2017).

- 49. Rose, A. et al. LandScan Global 2019. Oak Ridge National Laboratory, Oak Ridge, TN (2020).
- 50. Oyola, S. O. et al. Whole genome sequencing of *Plasmodium falciparum* from dried blood spots using selective whole genome amplification. Malar. J. 15, 597 (2016).
- 51. Cowell, A. N. et al. Selective whole-genome amplification Is a robust method that enables
  scalable whole-genome sequencing of *Plasmodium vivax* from unprocessed clinical samples.
  mBio 8, (2017).
- 52. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform.
  Bioinformatics 25, 1754–1760 (2009).
- 53. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing
  next-generation DNA sequencing data. Genome Res. 20,1297–1303 (2010).
- 54. Miles, A. et al. Indels, structural variation, and recombination drive genomic diversity in *Plasmodium falciparum*. Genome Res. 26, 1288–1299 (2016).
- 55. de Oliveira, T. C. et al. Population genomics reveals the expansion of highly inbred *Plasmodium vivax* lineages in the main malaria hotspot of Brazil. PLoS Negl. Trop. Dis. 14,
  e0008808 (2020).
- 56. Danecek, P. et al. The variant call format and VCFtools. Bioinformatics 27, 2156-2158.
- 57. Purcell, S. et al. PLINK: A tool set for whole-genome association and population-based
  linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
- 58. Csárdi, G. et al. igraph for R: R interface of the igraph library for graph theory and networkanalysis. R package version 1.3.5 (2022).
- 59. Oksanen, J. et al. vegan: Community Ecology Package. (2022). R package version 2.6-4(2022).
- 60. Natural Earth free vector and raster map data at 1:10m, 1:50m, and 1:110m scales.
  Available at https://www.naturalearthdata.com/ (2024).
- 755
- 755
- 756
- 757
- 758
- 759
- 760

Fig. 1





е



Age group (by gender)



a

b



Fraction genome identical-by-descent (IBD)



Fig. 4







Case flow (as % of total)



Incidence normalized by sampling area

Fraction cases



ns

С

0.40

0.30 -

0.20 -

0.10 -

P. falciparum

ns

P. vivax

761

# 762 Supplementary Text 1

# 763 **Relationships between samples collected in Guyana and Venezuela**

764 We assessed whether our small comparator set from Venezuela (22 monoclonal samples) could 765 indicate the presence of cross-border parasite genetic divergence and transmission of imported 766 strains within Guyana. The Venezuelan comparator set primarily represents infections from the 767 eastern states of Bolívar and Sucre. Two P. falciparum samples (PW0065-C and SPT26229) 768 and one P. vivax sample (CEM541 Pv-9) lack travel history data. In P. falciparum, the IBD 769 distribution for sample-pairs representing comparisons within Guyana (median = 0.283) 770 appeared right-shifted (Wilcoxon test, W= 57691375, p < 0.001) relative to the IBD distribution 771 for sample-pairs representing cross-border comparisons (median = 0.261, Supplementary Fig. 772 9a). To further visualize this divergence signal in *P. falciparum* and to screen for imported 773 transmission, we mapped the highest IBD value observed for each sample with respect to 774 samples representing Venezuela ('MaxVZ', Supplementary Fig. 9b). Only three infections from 775 Guyana showed aberrant (>2 sd above average) maxVZ. Two of these three (G4G410 and 776 G4G1043) were clonal (>0.90 IBD) with respect to Venezuelan infections Venez 001 F1 and 777 PW0065-C (Supplementary Fig. 9c,d). Highly aberrant (> 3 sd above average) IBD relative to 778 G4G410 or G4G1043 occurred in five of nine Venezuelan infections but in just one of 527 779 Guyanese samples. These observations suggest that G4G410 and G4G1043 represent cases 780 of imported transmission from Venezuela into Guyana. Observing just two such cases in the 781 sample set suggests that imported transmission is infrequent (despite health posts near the 782 border frequently experiencing foreign cases - see cyan pie slices in Supplementary Fig. 12) 783 but verification is required with larger Venezuelan sample sets.

In *P. vivax,* G-G and G-V distributions were also statistically distinguishable (p<0.001) but were</li>
 very close in absolute overlap (median 0.046 vs. 0.041 (respectively) <u>Supplementary Fig. 9e</u>)).

- 786 Although scarce, aberrant maxVZ values (>2 sd above average) occurred within Guyana more
- 787 frequently in *P. vivax* (7/474) than in *P. falciparum* (3/528) and occurred within Venezuela less
- frequently in *P. vivax* (5/13) than in *P. falciparum* (6/9) (Supplementary Fig. 9f vs.
- 789 <u>Supplementary Fig. 9b</u>).
- 790 Principal component analysis using direct SNP data (IBS instead of IBD, Supplementary Fig.
- 791 <u>9g</u>) did not help clarify Guyana-Venezuela population patterns in either species. Maps of
- alternative IBD features (e.g., maximum intrachromosomal IBD tract length) were also difficult to
- 793 interpret (Supplementary Fig. 9h-m).



Supplementary Fig. 1 Intra-annual variation in *P. falciparum* and *P. vivax* cases in Guyana. Points represent weekly reported cases and lines represent 30-day rolling averages in 2018 and 2019.



b



**Supplementary Fig. 2 Epidemiological zoning based on connectivity analysis in Guyana.** Diagnosis and infection localities (inferred based on reported stay 2 weeks prior to diagnosis) were grouped into 27 epidemiological zones. Though not automated using any fixed thresholds, grouping decisions were partially informed by river distance calculation and resistance surface analysis. a) To measure river distances, localities were first fitted to nearest river coordinates (red and blue points, respectively). Distances along rivers were then measured between assigned coordinates (e.g., Aranka to Serenamu, bottom plot). b) For resistance surface analysis, localities were plotted on a mobility friction map obtained from <a href="https://malariaatlas.org/">https://malariaatlas.org/</a>. Light grey and white represent highest conductance to motorized travel. The right plot illustrates how a least cost path (black line) inferred for Las Cristinas (Venezuela) to Bartica (Guyana)) matches the flow of the Cuyuni River. Yellow and green represent highest conductance to motorized travel.



**Supplementary Fig. 3 Relative** *P. falciparum* prevalence with respect to age and gender in Guyana. Boxplots summarize monthly variation (median and quartiles) in the percent of malaria cases representing *P. falciparum* in 2019. Brown and red represent values for male and female cases, respectively.



Supplementary Fig. 4 *P. falciparum* and *P. vivax* case counts be age, gender, and ethnicity in Guyana. Colors in stacked bar charts indicate self-reported ethnicities (key at left) among malaria patients in 2019.



Supplementary Fig. 5 *P. falciparum* and *P. vivax* pairwise nucleotide diversity among epidemiological zones in Guyana. Boxplots summarize variation (median and quartiles) in windowed  $\pi$  values (y-axis) for each epidemiological zone (x-axis) represented by  $\geq$  10 genomic samples (see top) in 2020-21.



10 -З 50

P. vivax



Supplementary Fig. 6 P. falciparum and P. vivax clustering relationships in Guyana and Venezuela. Clusters (circles) represent groups of samples in which each sample is related to at least one other sample in the group at the specified IBD threshold (x-axis, decreasing from left). Circle sizes represent cluster membership sizes, minimally two. Clusters adjacent on the x-axis are connected by a line if the right (lower threshold) cluster contains all the members of the left (higher threshold) cluster. Arrows at left indicate P. falciparum clonal group IDs mapped in Supplementary Fig. 8. Analysis includes samples from Guyana (2020-21) and Venezuela (2015-16 and 2019).

а





Supplementary Fig. 7 Spatiotemporal variation in *P. falciparum* clonal group membership in Guyana. The y-axis lists the clonal groups detected in each epidemiological zone (colors) in 2020-21. Group detection (circle size represents the number of group members detected) is plotted by month on the x-axis. **a)** When detections occur in multiple months per zone, these are connected by black lines. Arrows indicate instances where detection is temporally aggregated, i.e., a 4 month window contains  $\geq$ 3 group members and also represents >50% of all members within that zone. **b)** In the majority of zones, membership detection does not occur in multiple months. Plots are split into two pages using flipped axes only to fit figure dimensions.

Mar 2021 Apr 2021 May 2021 Jun 2021



(Supp. Fig. 8 – continues on next page)

# b



Supplementary Fig. 8 *P. falciparum* clonal group mapping in Guyana and Venezuela. a) Large clonal groups (≥10 members each) in 2020-21. b) Selected clonal groups highlighted in main text (2015, 2019, and 2020-21). Colors indicate group IDs (key at top left). Star symbols indicate clonal groups with partial membership in Venezuela (#65 in Sucre municipality (2019), Bolívar state, and #20, specific locality unknown (2015)). Semi-transparent symbols indicate the presence of other clonal groups aside than those being highlighted.





<sup>(</sup>Supp. Fig. 9 – continues on next pages)



P. falciparum maximum genome-wide IBD vs. Venezuelan comparator set (MaxVZ)

b



# P. falciparum genome-wide IBD vs. G4G410

(Supp. Fig. 9 – continues on next pages)



# P. falciparum genome-wide IBD vs. G4G1043

(Supp. Fig. 9 - continues on next pages)





G-G -

G-V -----

е



P. vivax maximum genome-wide IBD vs. Venezuelan comparator set (MaxVZ)

f



g



P. falciparum average genome-wide IBD vs. Venezuelan comparator set

h



P. falciparum maximum intra-chromosomal IBD tract length vs. Venezuelan comparator set







P. vivax average genome-wide IBD vs. Venezuelan comparator set



P. vivax maximum intra-chromosomal IBD tract length vs. Venezuelan comparator set



P. vivax average intra-chromosomal IBD tract length vs. Venezuelan comparator set

Supplementary Fig. 9 Differentiation between Guyanese and Venezuelan P. falciparum and P. vivax samples. Samples represent 2020-21 (Guyana) and 2015-16 + 2019 (Venezuela). a) IBD density curve for P. falciparum sample-pairs representing within-Guyana comparisons (G-G, solid line) and Guyana-Venezuela comparisons (G-V, dashed line). b) For P. falciparum, map of maximum genome-wide IBD vs. any Venezuelan sample (MaxVZ). c) For P. falciparum, map of genome-wide IBD vs. G4G410 (including comparison of G4G410 to itself (i.e., 100% IBD)). d) For P. falciparum, map of genome-wide IBD vs. G4G1043 (including comparison of G4G1043 to itself (i.e., 100% IBD)). e) IBD density curve for P. vivax sample-pairs representing within-Guyana comparisons (G-G, solid line) and Guyana-Venezuela comparisons (G-V, dashed line). f) For P. vivax, map of maximum genome-wide IBD vs. any Venezuelan sample (MaxVZ). g) Principal component analysis in P. falciparum (left) and P. vivax (right). Sample points plotted on PC1 vs. PC2 are colored according to epidemiological zone, and shape indicates country. All Venezuelan samples are classified to a single zone (yellow triangles). Analysis uses sites with >2% minor allele frequency and no missing genotype calls. h) For P. falciparum, map of average genomewide IBD vs. any Venezuelan sample. i) For P. falciparum, map of maximum intra-chromosomal IBD tract length vs. any Venezuelan sample. i) For P. falciparum, map of average intra-chromosomal IBD tract length vs. any Venezuelan sample. k) For P. vivax, map of average genome-wide IBD vs. any Venezuelan sample. I) For P. vivax, map of maximum intra-chromosomal IBD tract length vs. any Venezuelan sample. m) For P. vivax, map of average intra-chromosomal IBD tract length vs. any Venezuelan sample. In each map, points are colored based on the standard deviation of the IBD metric from the mean (see color scale at right). Points with higher values are plotted above points with lower values, i.e., are not obscured. Circles represent samples with travel history recorded to the locality level (i.e., using specific coordinates). Squares represent samples with travel history recorded to the municipality level (coordinates are placed within known malaria areas of the municipality (black perimeter)). Travel history for sample CEM526 Pv-2 (diamond) is recorded only to the state level (Barinas (Ba), white perimeter)). Its coordinates are placed arbitrarily within Ba. Samples CEM541 Pv-9, PW0065-C, and SPT26229 (triangles and/or text annotation) do not contain any travel history details. Star symbols are used for clonal samples with representation in both Guyana and Venezuela. Municipalities are abbreviated within the Venezuelan states of Bolívar (EC (El Callao), GS (Gran Sabana), He (Heres), Pi (Piar), Sifontes (Sifontes), Su (Sucre)), Sucre (Be (Benítez), Ca (Cajigal), and Ri (Ribero)), and Miranda (Gu (Guaicaipuro)).



Supplementary Fig. 10 *P. falciparum* and *P. vivax* IBD with respect to time difference in sampling dates in Guyana. Boxplots summarize variation (median and quartiles) in time (days) between sampling for different IBD categories (increasing from low to high (clonal) on x-axis) in 2020-21.



Supplementary Fig. 11 Mantel correlograms for *P. falciparum* and *P. vivax* in Guyana. Mantel correlation coefficients (r) are plotted on the y-axis for successive (non-overlapping) spatial distance classes (bars) separating infection localities in 2020-21. Black bars indicate significant r (p < 0.05) between genetic and spatial distance matrices. Top plots use 1-p99 IBD frequency and bottom plots use  $\leq 0.50$  IBD frequency for the genetic distance matrix. Positive r represents isolation-by-distance, i.e., that genetic distance increases with spatial distance.



Supplementary Fig. 12 *P. falciparum* and *P. vivax* case flow in Guyana. Pie icon sizes represent the number of cases sampled within each epidemiological zone in 2019. Black slices represent the fraction of cases representing patients that reported having stayed in the same epidemiological zone 2 weeks prior to diagnosis. Grey slices represent the fraction of cases representing patients that reported having stayed in a different epidemiological zone 2 weeks prior to diagnosis. Case flow segments are mapped for such 'non-local' cases. These segments connect the reported location of prior stay with arrows to the location of diagnosis. Arrows are used if the location of diagnosis is considered an endemic zone (e.g., for this reason only solid lines connect to coastal zones around Georgetown). The number of case flow events recorded between zones is represented by segment color, increasing from yellow through orange and red to blue (see scale). The analysis uses 13,641 cases for which information on location of diagnosis is available.



% P. falciparum cases representing local infection

**Supplementary Fig. 13 Rates of local infection for** *P. falciparum* and *P. vivax* in Guyana. For each epidemiological zone (points), the percentage of *P. falciparum* cases representing local infection (x-axis) is plotted against the percentage of *P. vivax* cases representing local infection (y-axis) in 2019. Values correspond to black pie slices in Supplementary Fig. 12. Blue is used when higher values occur for *P. falciparum*, green is used when higher values occur for *P. falciparum*, green is used when higher values are equal between species.



Supplementary Fig. 14 Relationship between the relative frequency of parasite p99 IBD and patient case flow detected between epidemiological zones in *P. falciparum* and *P. vivax* in Guyana. Genetic data (y-axis) represents 2020-21. Epidemiological (case flow) data (x-axis) represents 2019. Point color indicates the spatial distance separating the zones being compared. Comparisons represented by  $\leq$ 50 comparisons are excluded. Pearson correlation is statistically significant in *P. falciparum* but not in *P. vivax*. Grey shading indicates 95% confidence intervals predicted by linear regression (dashed line).



P. falciparum P. vivax

**Supplementary Fig. 15 Linkage decay in** *P. falciparum* and *P. vivax* in Guyana. Average linkage values (r<sup>2</sup>) between SNP sites are plotted in sliding 10 kbp windows (step size = 200 bp) for samples from 2020-21.



Supplementary Fig. 16 Complexity of infection values for *P. falciparum* and *P. vivax* in Venezuelan and non-Venezuelan patients with infections attributed to NDC VII-2 in Guyana. NDC VII-2 is highlighted in green in the map. Upper plots represent patients of non-Venezuelan nationality and lower plots represent patients of Venezuelan nationality (see large brackets at left). For each malaria species and patient gender, horizontally stacked bars represent complexity of infection (COI) values contributing to total observed polyclonality rate (full length of bar on x-axis) in 2020-21. Orange = 2 strains, yellow = 3 strains, and red = 4 strains. *P. vivax* polyclonality rate is significantly elevated in female Venezuelan patients vs. male Venezuelan patients (Chi-squared test). Differences are non-significant (ns) for other indicated comparisons (see small brackets at right).



#### **VECTOR CONTROL SERVICES - MINISTRY OF PUBLIC HEALTH**

Original (Regional Health Office), Copy (Health Facility); Fever: Current (0 - 5 days), Recent (6 - 30 days), No fever (in the last 31 days).

**Supplementary Fig. 17 Malaria case form underlying patient metadata records analyzed from Guyana.** Form records of sampling date, sampling location, patient gender, patient age, patient nationality, patient ethnicity, location of patient stay 2 weeks prior to diagnosis, and infecting species (microscopy or RDT result) were provided to study authors using anonymized patient codes. Only cases marked 'New' and 'Passive' were analyzed. The same form was used for 2019 and 2020-21 sample sets.